Skip to main content

Table 4 Disposition of polymorphisms involved in nevirapine metabolism

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

 

Total

Hepatotoxicity

No hepatotoxicity

p*

n = 362

n = 8

n = 354

ABCB1 c.3435/rs1045642, n (%)

   

0.019

 CC

86 (23.8)

5 (5.8)

81 (94.2)

 

 CT

178 (49.2)

1 (0.6)

177 (99.4)

 

 TT

98 (27.0)

2 (2.0)

96 (98.0)

 

CYP2B6 c.516/rs3745274, n (%)

   

0.706

 GG

196 (54.1)

6 (3.1)

190 (96.9)

 

 GT

141 (39.0)

2 (1.4)

139 (98.6)

 

 TT

25 (6.9)

0 (0.0)

25 (100.0)

 

CYP3A4/A5 **, n (%)

   

0.602

Extensive

58 (16.1)

0 (0.0)

58 (100.0)

 

Intermediate

270 (74.5)

8 (3.0)

262 (97.0)

 

Poor

25 (6.9)

0 (0.0)

25 (100.0)

 

 nd

9 (2.5)

0 (0.0)

9 (100.0)

 
  1. Abbreviations: n number, nd not determined, ABCB ATP Binding Cassette Subfamily B, CYP Cytochrome P450 enzyme
  2. *χ2 test ** CYP3A4*22/rs35599367 and CYP3A5*3/rs776746 combined genotypes for comprehensive functional evaluation [33, 34]